Harnessing Genetic Medicine & saRNA to Transform Oncology

Developing in vivo CAR, immuno-oncology, and cancer vaccine platforms.

Our Mission

We're dedicated to advancing genetic medicine and transforming cancer treatment. Our groundbreaking technology enables unparalleled gene expression and therapeutic potency, making it ideal for developing enhanced in vivo CAR-T therapies.


Our innovative technology is also catalyzing advancements in immuno-oncology and cancer vaccines -- offering new hope in the battle against cancer.

How we do it

Chimeron Bio's unique approach achieves superior expression and broader dynamic range compared to other leading RNA technologies.

Single Package

Deliver multi-pathway therapies with a single package

Exceptionally Large Payloads

Able to carry exceptionally large RNA payloads, combined with self-amplification to deliver large proteins or multiple proteins

Multiple Gene Delivery

Co-deliver RNA expressing multiple different proteins

Targeted Uptake

Potential for targeted delivery via envelope + ligand of choice

In the News

The Latest from Chimeron Bio

Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development

Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development

read more
900 900 Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award

Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award

read more
750 750 Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors

Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors

read more
300 300 Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio Welcomes Kevin Heyeck as New CEO

Chimeron Bio Welcomes Kevin Heyeck as New CEO

read more
300 300 Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates

Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates

read more
206 206 Chimeron Bio | Redefining Cancer Therapeutics